美股新聞 標題聯播 · 近 24 小時 294 則 · 33 個來源 · 最新 9/20 03:26
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · KYMR近 30 天 5 則 · 第 1 / 1 頁
- Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?
- Can KT-621 Mark a Turning Point for Kymera Therapeutics?
- Kymera Therapeutics to Participate in Upcoming September Investor Conferences
- Kymera's KT-621 Has 'Oral Dupixent' Potential, but Valuation Limits Upside, RBC Says
- Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses
- Kymera Therapeutics (KYMR) Q2 2026 Earnings Call Transcript
- Nurix Therapeutics' STAT6 Degrader Likely to Receive Increased Recognition, RBC Says
- KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments
- Accelerated KT-621 Trial and Narrower Loss Might Change The Case For Investing In Kymera Therapeutics (KYMR)
- Kymera Therapeutics, Inc. Q2 2026 Earnings Call Summary
- Kymera Therapeutics Q2 Earnings Call Highlights
- Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimates
- Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
- Humana upgraded, Las Vegas Sands downgraded: Wall Street's top analyst calls
- Here Are Wednesday’s Top Wall Street Analyst Research Calls: Bloom Energy, Dave, Fiverr, Humana, Las Vegas Sands, Lemonade, Procter & Gamble, SK hynix, Wix.com, and More
- Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026
- Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
- Is Kymera Therapeutics Poised for a Breakthrough With KT-621?
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。